Overview

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, double-blind, placebo-controlled study.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Dopamine